Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma-Reference-Cited by-同舟云学术

Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma

Published:2019-01-06 Issue:6 Volume:185 Page:1055-1070
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chu Yaya¹,Gardenswartz Aliza¹,Termuhlen Amanda M.²,Cairo Mitchell S.¹³⁴⁵⁶^ORCID

Affiliation:

1. Department of Pediatrics New York Medical College Valhalla NYUSA

2. Department of Pediatrics University of Minnesota Medical School Minneapolis MN USA

3. Department of Medicine New York Medical College Valhalla NYUSA

4. Department of Pathology New York Medical College Valhalla NYUSA

5. Department of Microbiology & Immunology New York Medical College Valhalla NYUSA

6. Department of Cell Biology & Anatomy New York Medical College Valhalla NY USA

Funder

St. Baldrick's Foundation

National Cancer Institute

National Heart, Lung, and Blood Institute

Pediatric Cancer Research Foundation

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15753

Reference108 articles.

1. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

2. Targeted IL-15-based Protein Fusion Complexes as Cancer Immunotherapy Approaches

3. Advantages and clinical applications of natural killer cells in cancer immunotherapy

4. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

5. Blinatumomab significantly enhanced cytotoxicity and T‐cell cytokine secretion against Burkitt lymphoma (BL) and primary mediastinal B‐cell lymphoma (PMBL);Awasthi A.;British Journal of Haematology,2018

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma;Best Practice & Research Clinical Haematology;2023-03

2. Lymphomas;Pediatric Surgery;2023

3. Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma;Leukemia & Lymphoma;2022-10-19

4. The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients;Cancers;2022-03-18

5. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL);Current Treatment Options in Oncology;2022-03